Steve has a long history of working for prestigious pharmaceutical companies like Pfizer and GSK. He has a breadth of expertise in drug development strategy and management, as well as scientific leadership in a variety of disease areas. His knowledge of translational pharmacology and immunology has been essential to the development of several therapeutic modalities from the discovery stage to the clinical stages. It has also stimulated organizational investment in cutting-edge assets and innovative drug development platforms. Steven will use his vast experience in cross-functional teamwork, strategic planning, and senior leadership at NTx to propel the business’s R&D projects to new heights.
After raising $47.5 million in Series B financing and working tirelessly for over eight years to develop and advance NTx technologies, Alex Koglin, the company’s founder and former CSO, has made the decision to take a break and rejuvenate.
The foundation of NTx is Alex’s astute observations. According to Jamie Coffin, CEO of NTx, “he has built an outstanding team of scientists and positioned the company for accelerated growth.” They appreciate his leadership and the major contributions he made to the company’s success. We are thrilled to have Steve join the leadership team as we grow our business.
According to Steve Evans, NTx has developed a platform that has the potential to completely transform the drug research and development industry by significantly reducing the price and time needed to bring essential drugs to market. It is quite thrilling to become a part of the team at this crucial juncture in the business. He is eager to see our technology advance even further.
The healthcare sector is progressing because to Nature’s Toolbox, Inc. (NTx) next-generation biomanufacturing solutions. The Rio Rancho, New Mexico-based company NTx is creating cutting-edge tools like NTxpress® and NTxscribe® to make it possible to produce mRNA vaccines and protein treatments in an environmentally responsible and sustainable manner. The platform developed by NTx may grow from individualized medicine dosage to pandemic volume thanks to these readily scalable procedures.
